Found 1347 matching trials
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
PHASE3RATIONALE: Providing information that is tailored to answer patients' quest...
Location
Barbara Ann Karmanos Cancer Institute
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
PHASE1This Phase Ib/II, open-label, multicenter trial is designed to evaluate the...
Location
Multiple Locations
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
PHASE1This study is being done to assess the safety and tolerance of different do...
Location
Service Des Maladies Du Sang
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
PHASE2This is an open-label, Phase II interventional study in order to assess eff...
Location
University of Colorado Hospital
Autologous Vaccine for Follicular Lymphoma
PHASE1This phase I study will evaluate the safety and tolerability of an autologo...
Location
Multiple Locations
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
PHASE1To determine what side effects and what clinical effect, if any, the admini...
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
PHASE1This phase Ib/II trial studies the side effects and best dose of toll-like ...
Location
Stanford University, School of Medicine
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer
PHASE3RATIONALE: Radioactive iodine uses radiation to kill tumor cells. Giving io...
Location
Sussex Cancer Centre at Royal Sussex County Hospital
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
PHASE2RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may des...
Location
Knight Cancer Institute at Oregon Health and Science University
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
PHASE1The primary objectives of this study is to evaluate the safety and efficacy...
Location
Stanford Cancer Center